Taken together, these results show that BRCA2 mutations can be detected in a substantial proportion of high-risk prostate cancer patients and that the presence of a BRCA2 mutation is associated with a poor response to docetaxel in the majority, but not all patients. Here, BRCA2 is linked to Familial prostate cancer.